Form 4: Apogee Therapeutics Director, Mark McKenna, Acquires Stock Options

Director Mark McKenna acquired options to purchase 10,370 shares of Apogee Therapeutics common stock on June 5, 2024.

Summary

• On June 5, 2024, Mark C. McKenna, a director of Apogee Therapeutics, Inc. [APGE], acquired stock options.
• The transaction involved the acquisition of options to purchase 10,370 shares of common stock at an exercise price of $43.85.
• These options vest on the one-year anniversary of the grant date, contingent upon McKenna's continued service to the issuer.
• Following the reported transaction, McKenna directly owns options for 10,370 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director, which can be seen as a positive sign of confidence but doesn't provide substantial information about the company's overall performance.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be indicative of their sentiment towards the company's prospects.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment.

Key Dates